Therapeutic Use of Posaconazole for Cutaneous Purpureocillium lilacinum Infection Refractory to Itraconazole
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpureocillium lilacinum is a saprophytic fungus with a ubiquitous environmental distribution. Unfortunately, no standard treatment has yet been established for cutaneous P. lilacinum infections. Based on the in vitro antifungal susceptibility test, posaconazole has been considered an effective treatment option. We herein present a case involving a 72-year-old woman who visited our clinic due to a peripherally spreading, well-demarcated, asymptomatic, scaly, and erythematous patch on her forehead that had persisted for 4 months. She had been diagnosed with cutaneous P. lilacinum infection and had been treated with itraconazole (200 mg/day). However, the lesion recurred in the same area. Histopathological findings revealed suppurative granulomatous dermatitis with fungal elements. Fungal culture confirmed P. lilacinum regrowth. Posaconazole was selected to treat the recurrence of P. lilacinum infection. After 10 weeks of treatment, the lesion decreased dramatically without any adverse drug events. We recommend posaconazole as a treatment option for P. lilacinum infection refractory to itraconazole.
Abstract
Purpureocillium lilacinum is a saprophytic fungus with a ubiquitous environmental distribution. Unfortunately, no standard treatment has yet been established for cutaneous P. lilacinum infections. Based on the in vitro antifungal susceptibility test, posaconazole has been considered an effective treatment option. We herein present a case involving a 72-year-old woman who visited our clinic due to a peripherally spreading, well-demarcated, asymptomatic, scaly, and erythematous patch on her forehead that had persisted for 4 months. She had been diagnosed with cutaneous P. lilacinum infection and had been treated with itraconazole (200 mg/day). However, the lesion recurred in the same area. Histopathological findings revealed suppurative granulomatous dermatitis with fungal elements. Fungal culture confirmed P. lilacinum regrowth. Posaconazole was selected to treat the recurrence of P. lilacinum infection. After 10 weeks of treatment, the lesion decreased dramatically without any adverse drug events. We recommend posaconazole as a treatment option for P. lilacinum infection refractory to itraconazole.
참고문헌 (17)
- Luangsa-Ard J, "Purpureocillium, a new genus for the medically important Paecilomyces lilacinus", FEMS Microbiol Lett, 321, pp.141~149 (2011)
- 하남경, "A Case of Cutaneous Purpureocillium lilacinum Infection Looking like Psoriasis", 대한의진균학회지, 26(3), pp.72~76 (2021), 대한의진균학회
- Leung S, "Posaconazole : An update of its clinical use", Pharmacy, 3, pp.210~268 (2015)
- Sprute R, "Invasive infections with Purpureocillium lilacinum : clinical characteristics and outcome of 101 cases from FungiScope® and the literature", J Antimicrob Chemother, 76, pp.1593~1603 (2021)
- Bupha-Intr O, "Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology", oncology setting, 2021, 2021, pp.51, 177~219
- Hoenigl M, "Global guideline for the diagnosis and management of rare mould infections : an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology", Lancet Infect Dis, 21, pp.e246~e257 (2021)
- Monpierre L, "Species identification and in vitro antifungal susceptibility of Paecilomyces", Purpureocillium species isolated from clinical respiratory samples : A multicenter study, 2022, pp.8, 684~
- Martens JA, "Posaconazole versus voriconazole for primary treatment of invasive aspergillosis:a phase 3, randomised, controlled, non-inferiority trial", Lancet, 397, pp.499~509 (2021)
- Albert R, "Chronic subcutaneous infection of Purpureocillium lilacinum in an immunocompromised patient : Case report and review of the literature", Med Mycol Case Rep, 38, pp.5~8 (2022)
- Chen WY, "Successful treatment of recurrent cutaneous Purpureocillium lilacinum(Paeclomyces lilacinus)infection with posaconazole and surgical debridement", Acta Derm Venereol, 99, pp.1313~1314 (2019)
- Ezzedine K, "Cutaneous hyphomycosis due to Paecilomyces lilacinus", Acta Derm Venereol, 92, pp.156~157 (2012)
- Hu X, "Complicated multiple organ infection of Purpureocillium lilacinum and varicella-zoster virus infection in a patient with Evans'syndrome", Blood Sci, 4, pp.89~92 (2022)
- Martinez E, "Cutaneous Paecilomyces infection in an immunocompromised patient in the setting of postthrombotic syndrome successfully treated with posaconazole", JAAD Case Rep, 6, pp.1144~1146 (2020)
- McGeachie DL, "Recurrent cutaneous hyalohyphomycosis secondary to Purpureocillium lilacinum in an immunocompetent individual", Australas J Dermatol, 62, pp.e411~e413 (2021)
- Paul J, "Diagnostic and therapeutic challenges of treating opportunistic fungal cellulitis : a case series", BMC Infect Dis, 22, pp.435~ (2022)
- Xia XJ, "Cutaneous hyalophomycosis caused by Purpureocillium lilacinum in an autoimmune hemolytic anemia patient with previous pulmonary tuberculosis and cutaneous cryptococcosis infection", Mycopathologia, 186, pp.563~564 (2021)
- Sienkiewicz BM, "Comparison of clinical pharmacology of voriconazole and posaconazole", Contemp Oncol, 20, pp.365~373 (2016)